All trading involves risk. Ensure you understand those risks before trading.
All trading involves risk. Ensure you understand those risks before trading.

Oracle Q4 preview: Where next for Oracle stock?

Article By: ,  Former Market Analyst

When will Oracle report Q4 earnings?

Oracle is scheduled to publish fourth quarter and full year results covering the 3-month and 12-month periods to the end of May 2022 after US markets close on Monday June 13. The software company will hold a conference call at 1600 Central Time on the same day to discuss its performance.

 

Oracle Q4 earnings consensus

Wall Street is expecting Oracle to report total revenue of $11.68 billion in the fourth quarter of its financial year, up some 4.1% from the year before. That compares to 3% to 5% growth target set by the company. Analysts forecast quarterly adjusted EPS will fall 10.6% from last year to $1.38, at the upper end of the $1.35 to $1.39 guidance range provided by Oracle.

For the full year, analysts have pencilled-in a 4.4% rise in annual revenue to $42.26 billion and a 1.7% rise in adjusted EPS to $4.75.

 

Oracle Q4 earnings preview

Oracle, best known for its software and services such as Java, is on course to report its slowest growth in annual adjusted earnings in six years when it releases full year results, with the fourth quarter expected to mark the second consecutive period that EPS has declined.

Revenue growth has slowed in recent quarters due to a pullback in demand in some markets due to the uncertain economic outlook, with some analysts anticipating license sales for its infrastructure arm could struggle this quarter. Meanwhile, its hardware division that deploys equipment used by businesses setting up data centres may have continued to suffer from supply chain problems after CEO Safra Catz admitted the company ‘couldn’t meet every need as quickly as we would have liked’ in the last quarter. Still, demand for Oracle’s cloud products and the steady recurring income derived from its servicing arm means the company has been able to keep growing its topline. The tougher environment also meant short-term deferred revenues – representing the amount of sums locked-in for services yet delivered – came in below expectations in the last quarter.

Oracle has been shifting its focus toward the cloud for several years and investors have taken some comfort in the fact that growth in this area continues to remain strong, even if other parts of the business are having a tougher time.

Meanwhile, earnings have started to come under pressure amid rising costs. Its adjusted operating margin started to tighten in the last quarter and this is expected to have continued in the final quarter, with analysts pencilling-in a margin of 46.3% compared to 48.5% the year before. Operating costs jumped 8% in the last quarter, outpacing the 5% growth in revenue, as expenses rise across the business, particularly on R&D and its cloud services division. Higher interest costs on its debt also weighed on the bottom-line. Oracle also blamed the fact its investments in gene-sequencing firm Oxford Nanopore and chipmaker Ampere Computing, both of which suffered heavy falls in the period, for missing expectations in the last quarter – but said it believes both will ultimately deliver ‘strong returns’ for the company even if they could remain a drag in the shorter-term.

Investors will be looking for initial guidance for the new financial year, starting with what to expect in the first quarter. Wall Street anticipates Oracle will target 5.2% revenue growth to $10.23 billion and a 9.8% rise in adjusted EPS to $1.13 in the first three months of the new financial year.

Markets believe growth can continue to accelerate in the new financial year, with current consensus figures from Bloomberg suggesting Oracle can deliver 5.9% topline growth and a 10.4% jump in adjusted EPS during the 12 months to the end of May 2023.

It is worth noting that Oracle’s acquisition of Cerner for $28 billion was recently completed, providing a fresh catalyst for the new financial year. Cerner deals in health records and the pair plan to work together to ‘transform healthcare delivery by providing medical professionals with better information’. Oracle said it expected Cerner to immediately boost adjusted EPS in the first full year after closing and ‘contribute substantially more to earnings in the second fiscal year and thereafter’. Oracle has described healthcare as the ‘largest and most important vertical market in the world’ and Cerner will accelerate the company’s overall revenue growth over the coming years.

 

Where next for ORCL stock?

Oracle shares have collapsed over 30% since peaking at all-time highs over six months ago.

Although shares have rebounded since hitting a 14-month low of $67 last month, the downtrend remains intact. Having tried and failed to break above this downtrend late last week, the stock needs to break above the $72 mark to signal a breakout. From there, it can look to recapture the 50-day moving average at $75, the 100-day moving average at $77 and then the 200-day moving average at $85, which is roughly in-line with the peak seen in early April. Notably, the 31 brokers that cover Oracle believe there is more potential upside with an average target price of $92, a level not seen since last year.

The 14-month low should be treated as the initial floor for the stock, which must hold to avoid opening the door to $66 level of support seen throughout March 2021. Below there, the stock could find itself falling below $64 for the first time in 16 months. 

The RSI is in neutral territory and isn’t providing any signals at present, but there has been a notable drop in trading volumes over the last five to ten trading sessions whilst the stock has largely found higher ground to suggest the recent rebound could struggle to gain traction and that it could come under further pressure.

How to trade Oracle stock

You can trade Oracle shares with City Index in just four easy steps:

  1. Open an account, or log in if you’re already a customer 

    Open an account in the UK
    Open an account in Australia
    Open an account in Singapore

  2. Search for ‘Oracle’ in our award-winning platform
  3. Choose your position and size, and your stop and limit levels
  4. Place the trade

Or you can try out your trading strategy risk-free by signing up for our Demo Trading Account.

From time to time, StoneX Financial Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.

As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.

City Index is a trading name of StoneX Financial Pty Ltd.

The material provided herein is general in nature and does not take into account your objectives, financial situation or needs.

While every care has been taken in preparing this material, we do not provide any representation or warranty (express or implied) with respect to its completeness or accuracy. This is not an invitation or an offer to invest nor is it a recommendation to buy or sell investments.

StoneX recommends you to seek independent financial and legal advice before making any financial investment decision. Trading CFDs and FX on margin carries a higher level of risk, and may not be suitable for all investors. The possibility exists that you could lose more than your initial investment further CFD investors do not own or have any rights to the underlying assets.

It is important you consider our Financial Services Guide and Product Disclosure Statement (PDS) available at www.cityindex.com/en-au/terms-and-policies/, before deciding to acquire or hold our products. As a part of our market risk management, we may take the opposite side of your trade. Our Target Market Determination (TMD) is also available at www.cityindex.com/en-au/terms-and-policies/.

StoneX Financial Pty Ltd, Suite 28.01, 264 George Street, Sydney, NSW 2000 (ACN 141 774 727, AFSL 345646) is the CFD issuer and our products are traded off exchange.

© City Index 2024